MedTrace Logo

Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer

NCT06893861 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3100

Last updated 2025-03-25

No results posted yet for this study

Summary

The study involves the use of reagents or materials for diagnostic assessments that are not commercially available, specifically a metabolomic signature for screening endometrial carcinoma and/or other types of cancers, and follows a case-control design.

This study aims to achieve several objectives that contribute to evaluating the diagnostic potential of a specific "metabolomic signature" to be used for screening endometrial carcinoma. Specifically, the study seeks to assess the signature's discriminative ability in differentiating between benign endometrial neoplasms and neoplasms of different histological origins.

Conditions

  • Endometrial Carcinoma (EC)

Interventions

OTHER

Metabolomic profiling

Blood samples will be collected from these subjects, and following metabolomic profiling, the data will provide the foundation for training machine learning models capable of recognizing the metabolomic profiles of subjects with endometrial carcinoma and differentiating them from subjects with other conditions.

Sponsors & Collaborators

  • National Cancer Institute, Naples

    lead OTHER

Principal Investigators

  • Antonella De Luca · IRCCS I.N.T. "G. Pascale"

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-06
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06893861 on ClinicalTrials.gov